



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

RECEIVED

TECH CENTER 1600/2900

NOV 29 2001

**INFORMATION DISCLOSURE  
STATEMENT**

Docket Number:  
**1662/52202**

Application Number  
**09/829,621**

Filing Date  
**April 10, 2001**

Examiner  
**Not Assigned**

Art Unit  
**1615**

Invention Title  
**METHOD AND COMPOSITION FOR  
TREATING CANCER BY ADMINISTRATION OF  
APOPTOSIS-INDUCING CHEMOTHERAPEUTIC  
AGENTS**

Inventors  
**FLASHNER-BARAK**

Address to:  
Assistant Commissioner for Patents  
Washington D.C. 20231

I hereby certify that this correspondence is being deposited with  
the United States Patent and Trademark Office in an envelope  
addressed to:  
D.C. 20231, OR

Date

*Signature*  
**KENYON & KENYON**

1. In accordance with the duty of Applicants under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A duplicate copy of this communication is enclosed for charging purposes.

Dated:

*20 Nov 01*

By:

*Patrick J. Birde*  
Patrick J. Birde (Reg. No. 29,770)

**KENYON & KENYON**  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (telephone)  
(212) 425-5288 (facsimile)